Harvard Bioscience Reports Q3 Revenue of $20.6 Million and Net Loss of $1.2 Million
Harvard Bioscience Inc. reported Q3 2025 revenues of $20.6 million with a gross margin of 58.4%, alongside a net loss of $1.2 million. The company generated positive cash from operations and anticipates refinancing or repaying its debt in Q4. Guidance for Q4 2025 indicates increased demand and improved operations. Harvard Bioscience specializes in technologies for life science applications, serving various sectors globally.
Harvard Bioscience Inc. reported third quarter 2025 revenues of $20.6 million and a gross margin of 58.4%. The company generated positive cash from operations during the period. Harvard Bioscience expects to refinance or repay its debt in the fourth quarter. The company’s fourth quarter 2025 guidance reflects increased demand, a higher backlog, improved operations, and continued financial discipline. Harvard Bioscience develops and sells technologies and products for life science applications, serving academic, government, pharmaceutical, biotechnology, and contract research organizations globally. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harvard Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9569933-en) on November 06, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
